Quantcast

Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr Instagram
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
December 25, 2014, 04:30:27 PM

Login with username, password and session length


Members
Stats
  • Total Posts: 650394
  • Total Topics: 49656
  • Online Today: 173
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Second Pathway Behind HIV-associated Immune System Dysfunction Identified  (Read 1257 times)

0 Members and 1 Guest are viewing this topic.

Offline J220

  • Member
  • Posts: 587
From http://www.sciencedaily.com/releases/2007/09/070930144552.htm

Okay Bizmarek will truly appreciate this one, as it has to do with hiv's ability to turn off the body's immune system. Evidently the pathways discovered so far (PD-1 and CTLA-4) are very complex, and clinical trials years away, but as I said in another thread, any step forward is a good step. Cheers, J.

p.s. by the way, forgive the cut and paste practice, but there is just no way I could offer a concise summary of these science stories. It's just better to post the full articles, which are rather condensed anyway. In addition I don't like to put just a link and say "go read this"....

--------------------------------------------------------------------------------

Second Pathway Behind HIV-associated Immune System Dysfunction Identified

Science Daily — Researchers at the Partners AIDS Research Center at Massachusetts General Hospital (PARC-MGH) may have discovered a second molecular "switch" responsible for turning off the immune system's response against HIV. Last year members of the same team identified a molecule called PD-1 that suppresses the activity of HIV-specific CD8 T cells that should destroy virus-infected cells. Now the researchers describe how a regulatory protein called CTLA-4 inhibits the action of HIV-specific CD4 T cells that control the overall response against the virus.

"We've shown that a known regulator of the immune system, CTLA-4, is present in elevated levels on the virus-specific CD4 cells that should be managing the body's response against HIV, says Daniel Kaufmann, MD, of PARC and the MGH Infectious Disease Unit, a co-first author of the recently published article. "We also found that CTLA-4 expression rises as HIV infection progresses and that the molecule switches off CD4 cell function in a way that appears to be reversible."

Expression of the CTLA-4 protein is known to be elevated on activated T cells, those that have encountered a pathogen and are multiplying rapidly to mount an immune response. Studies in cancer patients have shown that the molecule serves to dampen the immune response, and some preliminary investigations in animals and humans have suggested a potential role in HIV infection. The current study was designed to examine how CTLA-4 may be involved in the dysfunction of HIV-specific T cells that leads to the immune-system breakdown of AIDS.

The researchers first found that CTLA-4 was overexpressed on the HIV-specific CD4 T cells of infected individuals who had not yet received antiviral treatment. Levels were highest in those with symptoms of acute infection and second highest in chronically infected participants. CTLA-4 expression was lowest among a group of participants whose immune systems were naturally able to suppress HIV replication without antiviral medications -- "elite controllers" in whom viral levels are too low to be detected.

Elevated CTLA-4 expression also correlated with signs of disease progression -- increased viral load and reduced overall CD4 count. While antiviral treatment caused viral loads to drop significantly after treatment began, it resulted in only modest and slow drops in CTLA-4 expression. In vitro tests of the effects of blocking the CTLA-4 molecule improved the function of HIV-specific CD4 cells. Comparing the effects of blocking CTLA-4 with those of blocking PD-1 or both molecules produced functional improvements that varied considerably between participants, signifying a complex relationship between the pathways controlled by the two molecules.

"Both of these pathways contribute to dysfunction of HIV-specific T cells and both may be considered targets for therapeutic intervention. But since their mechanisms are so complicated, further study is needed before clinical trials can be planned," says Kaufmann, an instructor in Medicine at Harvard Medical School (HMS).

"Understanding why the immune system fails to control HIV is essential for development of vaccines and new therapies" said Bruce Walker, MD, director of PARC-MGH and senior author of the study. "These studies suggest that the immune system is turning itself off prematurely in HIV-infected persons, and the big challenge now is to figure out if we can turn it back on, getting it to do what it is supposed to do, without causing collateral damage in the process." Walker is a professor of Medicine at HMS and a Howard Hughes Medical Institute (HHMI) investigator.

The report will appear in the journal Nature Immunology and is receiving early online release.

Co-first author of the Nature Immunology report is Daniel Kavanagh, PhD, also of PARC and MGH. Additional co-authors are Florencia Pereyra, MD, Elizabeth Mackey, Toshiyuki Miura, PhD, DM; Mark Brockman, Almas Rathod, Alicja Piechocka-Trocha, Brett Baker, Sylvie Le Gall, PhD, Michael Waring, Ryan Ahern, Kristen Moss, and Eric Rosenberg, MD, of PARC-MGH; John Zaunders and Anthony Kelleher, MBBS, PhD, St. Vincent's Hospital, Darlington, NSW, Australia; Sarah Palmer, PhD, and John Coffin, PhD, National Cancer Institute; Baogong Zhu, MD, and Gordon Freeman, PhD, Dana-Farber Cancer Institute. External support for the study came from the National Institutes of Health, HHMI and the Mark and Lisa Schwartz Foundation.

Note: This story has been adapted from material provided by Massachusetts General Hospital.
"Hope is my philosophy
Just needs days in which to be
Love of Life means hope for me
Born on a New Day" - John David

Offline milker

  • Member
  • Posts: 4,034
  • Protected phone sex
Re: Second Pathway Behind HIV-associated Immune System Dysfunction Identified
« Reply #1 on: September 30, 2007, 11:19:34 PM »
I'm not surprised, CTLA-4 is one of the pathways to apoptosis. PD-1 is not new, it's been discovered before 2006, i'm a bit surprised that they say "last year" but anyways I have a problem when people say that 99% of people have a dysfunctional immune system. The elite controllers to me are the ones that have a dysfunctional immune system. The CTLA-4, PD-1 and other pathways to cell death are normal, a cell with impaired DNA must die, it's natural. Elite controllers seem to have a dysfunctional apoptosis pathway that happens to be what we'd like to understand and take advantage of it to control cell death.

Milker
mid-dec: stupid ass
mid-jan: seroconversion
mid-feb: poz
mar 07: cd4 432 (35%) vl 54000
may 07: cd4 399 (28%) vl 27760
jul 07: cd4 403 (26%) vl 99241
oct 07: cd4 353 (24%) vl 29993
jan 08: cd4 332 (26%) vl 33308
mar 08: cd4 392 (23%) vl 75548
jun 08: cd4 325 (27%) vl 45880
oct 08: cd4 197 (20%) vl 154000 <== aids diagnosis
nov 2 08 start Atripla
nov 30 08: cd4 478 (23%) vl 1880 !!!!!!!!!!!!!!!!!!!!!!!!!!
feb 19 09: cd4 398 (24%) vl 430 getting there!
apr 23 09: cd4 604 (29%) vl 50 woohoo :D :D
jul 30 09: cd4 512 (29%) vl undetectable :D :D
may 27 10: cd4 655 (32%) vl undetectable :D :D

Now accepting applications from blowjob ninjas™

Offline Customer

  • Member
  • Posts: 98

Once this was titled "HIV turns off immune system", now it say: ""These studies suggest that the immune system is turning itself off... "
Of the two I believe the latter. It is the immune system who protects itself by turning off CD8-cells after seeing that it's response has not been successfull. And i doubt that just turning on Cd8 cells is going to do any good.



 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.